1	
2	
3	Draft ICCVAM Summary Review Document: The Low Volume
4	Eye Test
5	
6	
7	
8 9	Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM)
10	
11	
12 13	National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM)
14	
15	
16	National Institute of Environmental Health Sciences
17	National Institutes of Health
18	U.S. Public Health Service
19	Department of Health and Human Services
20	
21	
22	
23	April 1, 2009

24	Erratum: May 15, 2009
25	A typographical error in the Executive Summary of the draft ICCVAM LVET Summary
26	Review Document (SRD; April 1, 2009) incorrectly states that there is "no information on
27	the performance of known human corrosives in the LVET". Section 5.0 of the SRD
28	recognizes that there are limited data on such substances. Therefore, the Executive Summary
29	should instead indicate that there is "limited information on the performance of known
30	human corrosives in the LVET". We apologize for any confusion this oversight has created.
31	

24		Table of Contents	
25	Prefa	ace	V
26	Exec	eutive Summary	.vii
27	1.0	Background on Ocular Safety Testing	1
28	2.0	Regulatory Testing Requirements for Ocular Hazards	3
29	3.0	Principle of the Low Volume Eye Test (LVET)	7
30	4.0	Performance of the LVET vs. the Draize Rabbit Eye Test	.10
31 32	5.0	Performance of the LVET vs. the Draize Rabbit Eye Test Considering Human Study Data and Experience	
33	6.0	Summary	.20
34	7.0	References	.21
35 36 37	Appo	endix A Low Volume Eye Test (LVET) A.I.S.E. Submission To ECVAM Technical Dossier, February 2007	A-1

# Interagency Coordinating Committee on the Validation of Alternative Methods: Agency Representatives

40	Agency for Toxic Substances and Dis	eas <b>7</b> 9	Food and Drug Administration
41	Registry	80	Office of Science
42	• Moiz Mumtaz, Ph.D.	81	• Suzanne Fitzpatrick, Ph.D., D.A.B.T.
43	<b>Consumer Product Safety Commission</b>	on 82	Center for Drug Evaluation and Research
44	• Marilyn L. Wind, Ph.D. (Chair)	83	♦ Abigail C. Jacobs, Ph.D.
45	♦ Kristina Hatlelid, Ph.D.	84	Paul C. Brown, Ph.D.
46	Joanna Matheson, Ph.D.	85	Center for Devices and Radiological Health
	·	86	Melvin E. Stratmeyer, Ph.D.
47	Department of Agriculture	87	Vasant G. Malshet, Ph.D., D.A.B.T.
48	• Jodie Kulpa-Eddy, D.V.M. (Vice-Cha	<sup>111</sup> 88	Center for Biologics Evaluation and Research
49	♦ Elizabeth Goldentyer, D.V.M.	89	Richard McFarland, Ph.D., M.D.
50	<b>Department of Defense</b>	90	Ying Huang, Ph.D.
51	• Robert E. Foster, Ph.D.	91	Center for Food Safety and Nutrition
52	♦ Patty Decot	92	David G. Hattan, Ph.D.
53	Harry Salem, Ph.D.	93	Robert L. Bronaugh, Ph.D.
54	Peter J. Schultheiss, D.V.M., D.A.C.L.	A.M94	Center for Veterinary Medicine
55	<b>Department of Energy</b>	95	Devaraya Jagannath, Ph.D.
56	• Michael Kuperberg, Ph.D.	96	M. Cecilia Aguila, D.V.M.
57	♦ Marvin Stodolsky, Ph.D.	97	National Center for Toxicological Research
		98	William T. Allaben, Ph.D.
58	Department of the Interior	99	Paul Howard, Ph.D.
59	• Barnett A. Rattner, Ph.D.	100	Donna Mendrick, Ph.D.
60	Department of Transportation	101	Office of Regulatory Affairs
61	• George Cushmac, Ph.D.	102	Lawrence D'Hoostelaere, Ph.D.
62	♦ Steve Hwang, Ph.D.	103	National Cancer Institute
63	<b>Environmental Protection Agency</b>	104	• T. Kevin Howcroft, Ph.D.
	Office of Science Counting the many De	,105	♦ Chand Khanna, DVM, Ph.D.
64 65	Office of Science Coordination and Po • Karen Hamernik, Ph.D.	106	National Institute of Environmental Health Sciences
	1201011 120110111111, 1 11.2 .	107	• William S. Stokes, D.V.M., D.A.C.L.A.M
66	Office of Research and Development	108	♦ Raymond R. Tice, Ph.D.
67	♦ Julian Preston, Ph.D.	109	Rajendra S. Chhabra, Ph.D., D.A.B.T.
68	Stephanie Padilla, Ph.D.	110	Jerrold J. Heindel, Ph.D.
69	Office of Pesticide Programs	111	National Institute for Occupational Safety and
70	Deborah McCall	112	National Institute for Occupational Safety and Health
71	OECD Test Guidelines Program	113	• Paul Nicolaysen, V.M.D.
72	Jerry Smrchek, Ph.D.	114	♦ K. Murali Rao, M.D., Ph.D.
73			·
74		115	National Institutes of Health
		116	• Margaret D. Snyder, Ph.D.
75		117	National Library of Medicine
76		118	• Pertti (Bert) Hakkinen, Ph.D.
	• Dringing Lagaran and an artificial	119	♦ Jeanne Goshorn, M.S.
77 70	• Principal agency representative	:.120	Occupational Safety and Health Administration
78	♦ Alternate principal agency representati	121	• Surender Ahir, Ph.D.

22 Acknowledgements								
Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) Ocular Toxicity Working Group (OTWG)								
126 U.S. Consumer Product Safety 154 National Institute of Environ	mental							
127 Commission 155 Health Sciences								
128 Marilyn Wind, Ph.D., (ICCVAM Chair) 156 Mark Cesta, DVM, DACVP								
157 Raymond (Buck) Grissom, Ph								
129 <b>Department of Defense</b> 158 William S. Stokes, D.V.M., D.	A.C.L.A.M							
130 Harry Salem, Ph.D. 159 (Director, NICEATM)								
121 Department of Transportation 160 Raymond R. Tice, Ph.D.								
131 Department of Transportation	141							
132 Steve Hwang, Ph.D.  161 Occupational Safety and Hea	ilth							
133 U.S. Environmental Protection Agency 162 Administration (OSHA) 163 Surrender Ahir Ph D								
133 U.S. Environmental Protection Agency 163 Surrender Ahir, Ph.D. 134 Meta Bonner, Ph.D.								
135 Jonathan Chen, Ph.D. 164 European Centre for the Val	idation of							
136 Andrew Geller, Ph.D. 165 Alternative Methods Liais								
137 Karen Hamernik, Ph.D. 166 João Barroso	,011							
138 Masih Hashim, D.V.M., Ph.D. 167 Thomas Cole, Ph.D.								
139 Karen Hicks 168 Chantra Eskes, Ph.D.								
140 Marianne Lewis 169 Valerie Zuang, Ph.D.								
141 Deborah McCall								
142 Timothy McMahon, Ph.D. 170 Japanese Center for the Vali	dation of							
143 Mark Perry, Ph.D. 171 <b>Alternative Methods Liais</b>	son							
144 John Redden, Ph.D. 172 Hajime Kojima, Ph.D.								
145 Jenny Tao, Ph.D.								
146 U.S. Food and Drug Administration								
147 Robert Bronaugh, Ph.D.								
148 Paul C. Brown, Ph.D.								
149 Wiley Chambers, M.D.								
150 Suzanne Fitzpatrick, Ph.D., D.A.B.T.								
151 Abigail Jacobs, Ph.D. (OTWG Co-Chair)								
152 Donnie Lowther								
153 Jill Merrill, Ph.D. (OTWG Co-Chair)								
105 VIII 1/1011III, 1 II.D. (O 1 1/ O CO CIIWII )								

173 174	National Toxicology Progr Evaluation of Alternative Tox		e •
175 176 177	National Institute of Environmental Healt William Stokes, D.V.M., D.A.C.L.A.M. Director; Project Officer	th Scien	ces
178 179 180	Deborah McCarley Special Assistant; Assistant Project Officer		
181	<b>NICEATM Support Contract Staff (Integ</b>	rated L	aboratory Systems [ILS], Inc.)
182 183	David Allen, Ph.D. Senior Toxicologist/Principal Investigator	191 192	Linda Litchfield Meeting Coordinator/Admin. Asst.
184 185	Jonathan Hamm, Ph.D. Senior Staff Toxicologist	193 194	Greg Moyer, M.B.A. Project Manager
186 187 188	Nelson Johnson Senior Project Coordinator/Technical Writer	195 196	Catherine Sprankle Senior Communications Specialist
189 190	Elizabeth Lipscomb, Ph.D. Staff Toxicologist	197 198 199	James Truax Senior Project Coordinator/Technical Writer
200			

201	Preface
202	Accidental contact with hazardous chemicals frequently causes eye injury and visual
203	impairment. United States and international regulatory agencies currently use the Draize
204	rabbit eye test (Draize et al. 1944) to identify potential ocular hazards associated with
205	chemicals. The U.S. Consumer Product Safety Commission, U.S. Environmental Protection
206	Agency (EPA), U.S. Food and Drug Administration, and U.S. Occupational Health and
207	Safety Administration have testing requirements and guidelines for assessing the ocular
208	irritation potential of substances such as pesticides, household products, pharmaceuticals,
209	cosmetics, and agricultural and industrial chemicals.
210	Although ocular safety assessment has clearly helped to protect consumers and workers,
211	concerns have been raised about the humane aspects of the Draize rabbit eye test (Draize et al.
212	1944). Regulatory authorities have adopted various modifications that reduce the number of
213	animals used and the potential pain and distress associated with the procedure. Significant
214	progress has been made during the last decade. Now only one to three rabbits are required per
215	test, compared to six rabbits in the original protocol. Provisions have been added that allow for
216	animals with severe lesions or discomfort to be humanely euthanized.
217	The low volume eye test (LVET) was developed by Griffith et al. (1980) as an alternative
218	with the intent to both refine the Draize rabbit eye test and to potentially more closely predict
219	the accidental human response to ocular hazard due to the site of test substance application
220	(corneal surface) and decreased volume of exposure (10 $\mu$ L) used. However, this hypothesis
221	has yet to be clearly demonstrated, and thus the LVET has yet to be adopted as a reference
222	test method by any regulatory agency.
223	ICCVAM is now reviewing the validity of the LVET because LVET data are used to support
224	the validity of one of the in vitro test methods proposed in an in vitro testing strategy for
225	antimicrobial cleaning products (see ICCVAM 2009 Summary Review Document,
226	http://iccvam.niehs.nih.gov/methods/ocutox/antimicro/BRD.pdf). The OTWG and
227	NICEATM prepared a draft summary review document (SRD) that summarizes the current
228	validation status of the LVET based on available information and data obtained by
229	NICEATM. This draft ICCVAM SRD forms the basis for draft ICCVAM test method
230	recommendations, which are provided in a separate document.

- 231 An international independent scientific peer review panel (Panel) will be convened in public 232 forum on May 19-21, 2009, to develop conclusions and recommendations on the LVET. The 233 panel includes expert scientists nominated by ECVAM and JaCVAM and we anticipate that 234 these organizations will be able to use the independent report of the panel for their deliberations 235 and development of test method recommendations. The Panel will meet to consider this SRD 236 and to evaluate the extent to which the available information supports the draft ICCVAM test 237 method recommendations. ICCVAM will consider the conclusions and recommendations of the 238 Panel, along with comments received from the public and SACATM, and then finalize the SRD 239 and test method recommendations. These will be forwarded to Federal agencies for their 240 consideration and acceptance decisions where appropriate. 241 We gratefully acknowledge the organizations and scientists who provided data and information 242 for this document. We also acknowledge the efforts of those individuals contributing to the 243 preparation of this summary review document, including the following staff from the 244 NICEATM Support Contractor, Integrated Laboratory Systems, Inc.: David Allen, Ph.D., Jon 245 Hamm, Ph.D., Nelson Johnson, Elizabeth Lipscomb, Ph.D., Linda Litchfield, Gregory Moyer, 246 M.B.A., Catherine Sprankle, and Jim Truax. We also thank the members of the ICCVAM 247 OTWG, chaired by Karen Hamernik, Ph.D. (EPA) and Jill Merrill, Ph.D. (U.S. Food and Drug 248 Administration), and ICCVAM representatives who subsequently reviewed and provided 249 comments throughout the process leading to this draft version. We also want to thank Valerie 250 Zuang, Ph.D. and Dr. Hajime Kojima, Ph.D., the OTWG liaisons from the European Centre for 251 the Validation of Alternative Methods and the Japanese Center for the Validation of Alternative Methods, respectively, for their participation. 252 253 Marilyn Wind, Ph.D. Deputy Associate Executive Director 254 255 Directorate for Health Sciences 256 U.S. Consumer Product Safety Commission Chair, ICCVAM 257 258 259 William S. Stokes, D.V.M., D.A.C.L.A.M. 260 Rear Admiral, U.S. Public Heath Service 261 Director, NICEATM 262 Executive Director, ICCVAM
- 263 March 2009

## 264 Executive Summary

265 Accidental eye injury due to contact with hazardous chemicals represents a major cause 266 of visual impairment. U.S. and international regulatory agencies currently use the Draize 267 rabbit eye test (Draize et al. 1944) as the preferred method to identify potential ocular 268 hazards associated with such chemicals. This procedure involves the introduction of 269 100µL of the test substance into the conjunctival sac of each animal's eye. Alternatives to 270 the Draize test have been explored to reduce the possibility of pain and distress during the 271 test procedure. One such method, the low volume eye test (LVET), was developed by 272 Griffith et al. (1980) as an alternative with the intent to both refine the rabbit eye test and 273 to potentially more closely predict the accidental human response to ocular hazard due to 274 the site of test substance application (corneal surface) and decreased volume of exposure 275 (10µL) used. However, this hypothesis has yet to be clearly demonstrated, and thus the 276 LVET has yet to be adopted as a reference test method by any regulatory agency. This 277 report provides a summary of the usefulness and limitations of the LVET as an 278 acceptable in vivo reference test method by reviewing the currently available scientific 279 literature. 280 The majority of available LVET data were generated with surfactant-based mixtures or 281 products, which produce only a mild ocular irritant response or no response. Gettings et 282 al. (1996) evaluated 25 surfactant formulations and their hazard classifications by the 283 EPA and GHS, and reported several incidences of underprediction of an ocular corrosive 284 or severe irritant response in the Draize rabbit eye test by the LVET method. While some have used these data to state that the Draize eye test is excessively overpredictive, there is 285 286 no information on the performance of known human corrosives in the LVET. 287 Freeberg et al. (1984) used both LVET and Draize to test 29 household cleaning products 288 for which human accidental exposure data are available. The authors concluded that the 289 LVET more accurately predicts the human accidental response to such substances. 290 Similarly, Freeberg et al. (1986b) used both LVET and Draize to test 14 cleaning 291 products, and compared the responses to human accidental eye exposures. They too 292 concluded that the LVET response more closely relates to the human experience than the 293 Draize rabbit test. Ghassemi et al. (1993) and Roggeband et al. (2000) both concluded

294 that the smaller volume (10µL) used in the LVET is more appropriate when compared 295 directly with human clinical data. However, the lack of available Draize rabbit eye test 296 data in these studies precludes any direct comparison with LVET. 297 This review of the validity of the LVET was undertaken because LVET data is used to 298 support the validity of one of the *in vitro* test methods proposed in an *in vitro* testing 299 strategy for antimicrobial cleaning products (see ICCVAM 2009 Summary Review 300 Document, http://iccvam.niehs.nih.gov/methods/ocutox/antimicro/BRD.pdf), Comparative 301 traditional Draize rabbit data with which to evaluate the accuracy of the LVET are only 302 available for limited types and numbers of substances (i.e., surfactant-containing personal 303 and household cleaning products), and comparative human data from clinical studies and 304 accidental exposures proposed to support its accuracy are largely with substances that are 305 mild or non-irritating. Ethical considerations have limited the severity of substances that can 306 be tested in human clinical studies. As a result, LVET comparisons to human clinical study 307 data are based on tests with mild irritant or substances not labeled as irritants. Such data 308 provide little assurance to the regulatory agencies charged with protecting public health that 309 the LVET can provide adequate protection from substances that may cause moderate or 310 severe ocular injuries in humans. 311 Thus, while the LVET is proposed as more likely to approximate the volume of a substance 312 that could enter the human eye experimentally, there are limited data to indicate whether it 313 can accurately identify the ocular hazard of substances known to cause moderate, severe, or 314 permanent human ocular injuries. In contrast, there are no documented instances where a 315 substance with a hazard category determined in the Draize eye test produced a more severe 316 hazard category response in humans following accidental exposures or ethical human 317 studies.

# 1.0 Background on Ocular Safety Testing

319	Accidental eye injury is a leading cause of visual impairment in the U.S., and many of these
320	injuries occur due to contact with workplace or household chemicals. According to the
321	National Institute of Occupational Safety and Health (NIOSH), each day about 2000 U.S.
322	workers have a job-related eye injury that requires medical treatment. Even more eye
323	injuries occur in the home, with about 125,000 eye injuries a year caused by accidents
324	involving common household products such as oven cleaner and bleach (source, American
325	Academy of Ophthalmology). U.S. regulatory agencies such as the Consumer Product
326	Safety Commission (CPSC), Environmental Protection Agency (EPA), Food and Drug
327	Administration (FDA), and Occupational Safety and Health Administration (OSHA) have
328	testing requirements for assessing the hazard potential of substances that may come in
329	contact with human eyes. These testing requirements have effectively protected consumers
330	and workers. The primary method currently accepted by U.S. and international regulatory
331	agencies for assessing ocular safety hazards is the Draize rabbit eye test (Draize et al. 1944).
332	Testing guidelines describing the procedure have been published (EPA OPPTS 870.2400
333	[EPA 1998]), OECD Test Guideline 405, [OECD 2002]) and several legislative statutes
334	have been enacted that enable government agencies to regulate a variety of substances with
335	the potential to pose a risk to ocular health (see Table 1-1).

#### Summary of Current U.S. Legislation Related to Ocular Health<sup>1</sup> 336 Table 1-1

Legislation (Year of Initial Enactment)	Agency	Substance
Food, Drug and Cosmetic Act (1938)	FDA	Pharmaceuticals and cosmetics
FIFRA (1947) and Federal Environmental Pesticide Control Act (1972)	EPA	Pesticides
FHSA (1964)	CPSC	Household products
FHSA (1964) and TSCA (1976)	Department of Agriculture and EPA	Agricultural and industrial chemicals
Occupational Safety and Health Act (1970)	OSHA	Occupational materials
Clean Air Act Amendments (1990)	Chemical Safety and Hazard Investigation Board and EPA	Accidentally released chemicals and air pollutants

337 Adapted from Wilhelmus (2001).

Abbreviations: CPSC = U.S. Consumer Product Safety Commission; EPA = U.S. Environmental Protection

338 339 Agency; FDA = U.S. Food and Drug Administration, FHSA = Federal Hazardous Substances Act; FIFRA =

340 Federal Insecticide, Fungicide, and Rodenticide Act; OSHA = Occupational Safety and Health

341 Administration; TSCA = Toxic Substances Control Act.

# 2.0 Regulatory Testing Requirements for Ocular Hazards

343	Depending on the legislative mandate of various regulatory agencies and their goals for
344	protecting human health, the classification of irritant responses evaluated by each agency
345	varies (Table 2-1). The EPA ocular irritation classification regulation and testing
346	guidelines (EPA 1998, 2003) are based on the most severe response in one animal in a
347	group of three or more animals. This classification system takes into consideration the
348	kinds of ocular effects produced, as well as the reversibility and the severity of the
349	effects. The EPA classifies substances into four ocular irritant categories, ranging from I
350	to IV (EPA 2003). Category I substances are defined as corrosive or severe irritants,
351	while classification from II to IV is based on decreasing severity of irritation, as well as
352	the time required for irritation to clear. Irritation that clears in 8 to 21 days is classified as
353	Category II, while irritation that clears within seven days is classified as Category III. For
354	Category IV substances, irritation clears within 24 hours.
355	The U.S. Federal Hazardous Substances Act (FHSA) guideline for ocular irritation
356	classification (CPSC 1995) categorizes a test substance as corrosive, irritant, or
357	nonirritant. The definition of a corrosive, according to the FHSA, is a substance that
358	causes visible destruction or irreversible alterations in the tissue at the site of contact
359	(CPSC 2004). FHSA classification depends on the number of test animals exhibiting a
360	positive ocular response within 72 hours after application of the test substance in the
361	conjunctival sac.
362	Hazard classification of ocular irritants in the European Union (EU) is characterized by
363	two risk phrases: 1) R36 denotes "Irritating to eyes"; 2) R41 denotes "Risk of serious
364	damage to the eyes" (EU 2001). These risk phrases are based on whether the levels of
365	damage, averaged across the 24-, 48- and 72-hour observation times for each ocular
366	lesion, fall within or above certain ranges of scores.
367	For the purpose of harmonizing the classification of ocular irritants internationally, the
368	United Nations (UN) Globally Harmonized System of Classification and Labeling of
369	Chemicals (GHS; UN 2003) includes two harmonized categories, one for irreversible
370	effects on the eye/serious damage to the eye (Category 1), and one for reversible effects
371	on the eye (Category 2). Reversible effects are further subclassified, based on the

- duration of persistence, as Category 2A ("irritating to eyes"; reverses within 21 days) and
- Category 2B ("mildly irritating to eyes"; reverses within seven days). The GHS
- 374 categories are based on severity of the lesions and/or the duration of persistence.

# 375 Table 2-1 Ocular Toxicity Classification Systems

Regulatory Agency (Authorizing Act)	Number of Animals	Observation Days (after treatment)	Mean score taken?	Positive response	Irritant/Non-irritant Classification
EPA (FIFRA, The Federal Environmental Pesticide Control Act, and TSCA)	At least 3	1 hr, 1, 2, 3, 7, 14, 21	No	-Maximum score in an animal used for classification -Opacity or Iritis $\geq 1$ or Redness or Chemosis $\geq 2$	-One or more positive animals needed for classification in categories below.  Category: I = Corrosive, corneal involvement, or irritation persisting more than 21 days II= Corneal involvement or irritation clearing in 8-21 days III = Corneal involvement or irritation clearing in 7 days or less IV = Minimal effects clearing in less than 24 hours
European Union	1 if severe effects are suspected or 3 if no severe effects are suspected	1, 2, 3 (observation until Day 21)	Yes	Mean study values (scores averaged over all animals in study over Days 1, 2, and 3) of: Opacity or Chemosis ≥ 2, Redness ≥ 2.5, or Iritis ≥ 1  OR  Individual animal mean values (scores for each endpoint are averaged for each animal over Days 1, 2, and 3) of: Opacity or Chemosis ≥ 2, Redness ≥ 2.5, or Iritis ≥ 1	R36 Classification (1) Mean study value where: 2 ≤ Opacity < 3 or 1 ≤ Iritis < 1.5 or Redness ≥ 2.5 or Chemosis ≥ 2 (2) If 2/3 tested animals have individual animal mean values that falls into one of the following categories: 2 ≤ Opacity < 3 1 ≤ Iritis < 2 Redness ≥ 2.5 Chemosis ≥ 2  R41 Classification (1) Mean study value where: Opacity ≥ 3 or Iritis > 1.5 (2) If 2/3 tested animals have individual animal mean values that fall into one of the following categories: Opacity ≥ 3 Iritis = 2 (3) At least one animal (at the end of the observation period, typically Day 21) where Opacity or Chemosis ≥ 2, Redness ≥ 2.5 or Iritis ≥ 1

Regulatory Agency (Authorizing Act)	Number of Animals	Observation Days (after treatment)	Mean score taken?	Positive response	Irritant/Non-irritant Classification
GHS: Irreversible Eye Effects	3	1, 2, 3 (observation until Day 21)	Yes	Mean animal values (over Days 1, 2, and 3) of: Opacity $\geq$ 3 and/or Iritis $\geq$ 1.5	-At least 2 positive response animals = Eye Irritant Category 1 -At least 1 animal with at least one of the following scores on Day 21 = Eye Irritant Category 1: Cornea ≥ 1 Iritis ≥ 1 Redness ≥ 2 Chemosis ≥ 2
GHS: Reversible Eye Effects	3	1, 2, 3 (observation until Day 21)	Yes	Mean animal values (over Days 1, 2, and 3) of: Opacity or Iritis ≥ 1 or Redness or Chemosis ≥ 2 and the effect fully reverses in 7 or 21 days	-At least 2 positive response animals and the effect fully reverses in 21 days = Eye Irritant Category 2A - At least 2 positive response animals and effect fully reverses in 7 days = Eye Irritant Category 2B  Definition of Full Reversal:  Cornea and Iritis scores < 1 and  Redness and Chemosis scores < 2
CPSC (Federal Hazardous Substances Act, FDA (Food, Drug, and Cosmetics Act), and OSHA (Occupational Safety and Health Act)	6 (12, 18 possible)	1, 2, 3	No	Opacity or Iritis ≥ 1 or Redness or Chemosis ≥ 2 for any animal on any day	1st Tier:  4 or more positive animals = Irritant  2-3 positive animals = Go to 2 <sup>nd</sup> Tier  3 or more positive animals = Irritant  1-2 positive animals = Go to 3 <sup>rd</sup> Tier

Abbreviations: CPSC = U.S. Consumer Product Safety Commission; FDA = U.S. Food and Drug Administration; EPA = U.S. Environmental Protection Agency; FIFRA = Federal Insecticide, Fungicide, and Rodenticide Act; GHS = United Nations (UN) Globally Harmonized System of Classification and Labeling of Chemicals; OSHA = U.S. Occupational Safety and Health Administration; TSCA = Toxic Substances Control Act

### 3.0 Principle of the Low Volume Eye Test (LVET)

The LVET is an *in vivo* rabbit eye test developed by Griffith et al. (1980), which, like the
Draize test, was designed to determine the extent of potential ocular hazard of a test
material by evaluating the ocular irritation response in the rabbit when administered to the
eye as a single dose. The LVET differs from the Draize rabbit eye test primarily by applying
10 μL (instead of 100 μL) of a test substance directly on the cornea (instead of the
conjunctival sac) (**Table 3-1**). Scoring of corneal, iridal, and conjunctival lesions in the
LVET is identical to that of the Draize rabbit eye test (**Table 3-2**).

Table 3-1 Comparison of Draize Eye Test and LVET Protocols

	LVET	Draize
Dose Volume	10 μL	100 μL
Dose Location	Applied directly onto the cornea	Applied into the lower conjunctival sac
Eyelid Closure	No forced eyelid closure	Eyelids held closed for one second
Scale for Scoring Ocular Lesions	Draize	Draize

LVET = low volume eye test

To date, the LVET has not been demonstrated as an adequately valid *in vivo* reference test method, and has yet to be formally adopted by any regulatory agency. For this reason, the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) is reviewing the validity of the LVET as an acceptable *in vivo* reference test method. The International Association for Soaps, Detergents and Maintenance Products (A.I.S.E.) submitted a background review document (BRD) in February 2007 to the European Centre for the Validation of Alternative Methods (ECVAM) for an independent peer review by their Scientific Advisory Committee (ESAC) (**Appendix A**). The A.I.S.E. BRD provides a comprehensive summary of available data and information with which to evaluate the usefulness and limitations of the LVET.

Since its original development, proponents of the LVET have suggested that it is a more appropriate *in vivo* reference test method for comparisons to *in vitro* data than is the Draize

rabbit eye test. This is primarily based on the assertion that the LVET is more representative

of the human response to a potential ocular hazard than the Draize rabbit eye test, given that the site (corneal surface) and volume of exposure used in the LVET more closely resemble that of accidental human exposure than does the Draize. As a result, a reported advantage of the LVET is that it underpredicts the Draize test and is thereby less overpredictive of the human response than the Draize test. However, definitive data to support this claim are not available.

Table 3-2 Scale of Weighted Scores for Grading the Severity of Ocular Lesions<sup>1</sup>

Lesion	Score <sup>2</sup>				
Cornea					
A. Opacity – Degree of density (area which is most dense is taken for reading					
Scattered or diffuse area – details of iris clearly visible	1				
Easily discernible translucent areas, details of iris slightly obscured	2				
Opalescent areas, no details of iris visible, size of pupil barely discernible	3				
Opaque, iris invisible	4				
B. Area of cornea involved					
One quarter (or less) but not zero	1				
Greater than one quarter but less than one-half	2				
Greater than one-half but less than three quarters	3				
Greater than three quarters up to whole area	4				
Score equals A x B x 5 Total maximum = 80					
•					
Iris					
A. Values					
Folds above normal, congestion, swelling, circumcorneal injection (any one or all of					
these or combination of any thereof), iris still reacting to light (sluggish reaction is					
positive)					
No reaction to light, hemorrhage; gross destruction (any one or all of these)	2				
Score equals A x 5 Total possible maximum = 10					
Conjunctiva					
A. Redness (refers to palpebral conjunctiva only)					
Vessels definitely injected above normal	1				
More diffuse, deeper crimson red, individual vessels not easily discernible	2				
Diffuse beefy red	3				
B. Chemosis					
Any swelling above normal (includes nictitating membrane)	1				
Obvious swelling with partial eversion of the lids	2				
Swelling with lids about half closed	3				
Swelling with lids about half closed to completely closed	4				
C. Discharge					
Any amount different from normal (does not include small amount observed in inner	,				
canthus of normal animals	1				
Discharge with moistening of the lids and hairs just adjacent to the lids	2				
Discharge with moistening of the lids and considerable area around the eye	3				
Score equals $(A + B + C) \times 2$ Total maximum = 20					

<sup>410</sup> From Draize et al. (1944)

- <sup>2</sup> The maximum total score is the sum of all scores obtained for the cornea, iris and conjunctiva. Scores of 0 are assigned for each parameter if the cornea, iris, or conjunctiva are normal.

### 4.0 Performance of the LVET vs. the Draize Rabbit Eye Test

As noted in the ECVAM BRD (**Appendix A**), most of the original data generated with the LVET were from surfactant-based mixtures or surfactant-based products. Most of the products tested produced only mild ocular irritant responses or are not ocular irritants. According to the ECVAM BRD (**Appendix A**), "most of the LVET results do not trigger an eye hazard classification based on European regulatory criteria and this correlates well with the extensive data on human experience with these products from the marketplace." However, a comparison of the substances that have been classified by the Draize rabbit eye test as ocular corrosives or severe irritants that have also been tested in the LVET indicates that the LVET routinely underpredicts the ocular corrosive or severe irritant response in the Draize, in many cases by more than one hazard category. This is illustrated by the results of Gettings et al. (1996) in their evaluation of 25 surfactant-containing formulations and the resulting hazard classifications according to the EPA and GHS classification systems (**Tables 4-1** and **4-2**).

Table 4-1 Performance of the LVET in Identifying Ocular Hazard Classification According to the EPA Classification System When Compared to Draize Rabbit Eye Test Results

EPA		LVET						
	EFA	I	II	III	IV	Totals		
	Ι	3	1	6	0	10		
	II	0	0	0	0	0		
Draize	III	0	0	9	2	11		
	IV	0	0	0	4	4		
	Totals	3	1	15	6	25		

EPA = Environmental Protection Agency ocular hazard classification; LVET = low volume eye test

Table 4-2 Performance of the LVET in Identifying Ocular Hazard Classification According to the GHS Classification System When Compared to Draize Rabbit Eye Test Results

GHS		LVET						
	GHS	1	2A	2B	Not Labeled	Totals		
	1	0	0	4	4	8		
	2A	0	0	0	0	0		
Draize	2B	0	0	0	1	1		
	Not Labeled	0	0	0	16	16		
	Totals	0	0	4	21	25		

GHS = United Nations Globally Harmonised System ocular hazard classification; LVET = low volume eye test

438439

444

446

447

449

450

436

437

433

434

435

Based on the data provided in **Tables 4-1** and **4-2**, it is clear that there are multiple instances of underprediction of an ocular corrosive or severe irritant response in the

Draize rabbit eye test by the LVET. When using the EPA hazard classification system,

442 60% (6/10) of Draize Category I substances were underpredicted as Category III (i.e.,

443 mild irritant) in the LVET (**Table 4-3**). When using the GHS hazard classification

system, all eight of the Draize Category 1 substances were underpredicted; 50% (4/8) as

Category 2B (i.e., mild irritant) and 50% (4/8) as Not Labeled (i.e., nonirritant) (**Table 4-**

4). These data raise concern about the capability of the LVET to reliably detect ocular

corrosives or severe irritants (i.e., EPA Category I, EU Category R41, or GHS Category

448 1).

Table 4-3 Extent of Underprediction of LVET vs. Draize Rabbit Eye Test Results According to the EPA Classification System

Draize Category	LVET Category	Product
Category I	Category II	HZY (Anti-dandruff shampoo)
Category I	Category III	HZA (Shampoo #7)
Category I	Category III	HZE (Gel cleanser)
Category I	Category III	HZF (Baby shampoo #2)
Category I	Category III	HZL (Foam bath)
Category I	Category III	HZR (Facial cleaning foam)
Category I	Category III	HZX (Shampoo #2)

Abbreviations: EPA = Environmental Protection Agency; LVET = low volume eye test

451 452

453

# 453 Table 4-4 Extent of Underprediction of LVET vs. Draize Rabbit Eye Test 454 Results According to the GHS Classification System

GHS Category	LVET Category	Product
Category 1	Category 2B	HZI (Skin cleanser)
Category 1	Category 2B	HZK (Bubble bath)
Category 1	Category 2B	HZS (Shower gel)
Category 1	Category 2B	HZY (Anti-dandruff shampoo)
Category 1	Not Classified	HZL (Foam bath)
Category 1	Not Classified	HZF (Baby shampoo #2)
Category 1	Not Classified	HZX (Shampoo #2)
Category 1	Not Classified	HZA (Shampoo #7)

Abbreviations: GHS = United Nations Globally Harmonised System ocular hazard classification;

456 LVET = low volume eye test

455

457

# 5.0 Performance of the LVET vs. the Draize Rabbit Eye Test Considering Human Study Data and Experience

Human data on potential ocular hazards are available either from accidental exposures or from clinical studies. Accidental exposures are not generally considered to be a reliable source of the true ocular hazard potential since such exposures are likely immediately followed by flushing the eyes with large volumes of water, and may not represent the most severe lesion that might be produced by such an exposure. Griffith et al. (1980) conducted a series of rabbit eye test studies using either 0.01 or 0.1 mL of substances "recognized as slightly irritating, moderately irritating, or severely irritating/corrosive to humans". Among the ocular corrosive or severe irritant substances were:

- Acetic acid (10%), which is referenced as a severe irritant based on splashes of vinegar (containing 4% to 10% acetic acid) reported to cause pain, conjunctival hyperemia, and occasionally permanent opacity of the human cornea
- Calcium hydroxide (hydrated lime), which is referenced as one of the most common causes of severe chemical burns of the eye (McLaughlin 1946; Grant 1974)
- Formaldehyde (38%), which is referenced for the range of injuries caused by splashes in the human eye from minor transient discomfort to severe, permanent corneal opacities (Grant 1974)

Although detailed animal data are not available, the summary data provided by Griffith et al. (1980) indicate that the lesions induced by 0.01 or 0.1 mL of these substances were not reversible within 21 days. However, such accidental exposures as human reference data make definitive quantitative measures of amount and time of exposure impossible to obtain. Ethical considerations, and results based largely on the Draize rabbit eye test, have limited the severity of substances that can be tested in human clinical studies. As a result, comparisons to human data are based on clinical study tests with mild irritant or substances not labeled as irritants. Such data provide little assurance to the regulatory agencies charged

486 with protecting public health that the LVET can provide adequate protection from 487 substances that may cause moderate or severe ocular injuries. 488 The fact that seemingly innocuous commercial consumer products were identified as ocular 489 corrosives or severe irritants by the Draize eye test in the evaluation described above could 490 be seen as providing support for the contention that the Draize eye test is excessively 491 overpredictive of the actual hazard to humans. However, because of the paucity of 492 information on the performance of known human corrosives in the LVET, these data cannot 493 simply be dismissed. 494 Several studies are cited in the ECVAM BRD (Appendix A) as supporting data for the 495 demonstrated usefulness of the LVET (Freeberg et al. 1984, 1986a, 1986b; Ghassemi et al. 496 1993; Roggeband et al. 2000). 497 5.1 Ghassemi et al. (1993) 498 Ghassemi et al. (1993) provides an evaluation of a single product, a liquid household 499 cleaner (pH 3) reportedly containing the following qualitative formula: non-ionic surfactant, 500 amphoteric surfactant, hydrotrope, solvent, and water. This study is a direct comparison of 501 LVET results to human clinical data (using either 10 µL or 100 µL doses) for the same test 502 substance. There are no Draize rabbit eve test data reported, and therefore no comparison of 503 the LVET to the standard eye test is possible. The ocular lesions that were produced in this 504 study and their subsequent time to clear would suggest that this product is a mild ocular 505 irritant (**Table 5-1**). The authors conclude that because the direct application to the human 506 eye using either 10 µL or 100 µL doses produced similar results, the smaller volume for 507 testing is more appropriate anatomically and physiologically based on eye volume capacity 508 and subsequent tear volume. 509

Table 5-1 Summary of Rabbit and Human Responses to an Undiluted Liquid Household Cleaner (Ghassemi et al. 1993)

Species	Species Ocular Number of Eyes Affected Mean		Mean CR at	Eyes Cleared/	Max Time-		
Species	Involved	Cornea	Iris	Conj	24 hr	4 hr Time-to-Clear	
Rabbit LVET	Cornea Iris Conj	3/3	2/3	3/3	2	2/4 days 1/7 days	7 days
Human (10μL)	Conj	0/10	0/10	10/10	0.1	1/1hr; 4/2hr; 6/4hr; 10/24hr	48 hr
Human (100μL)	Conj	0/10	0/10	10/10	0.2	1/1hr; 2/2hr; 9/24hr; 2/46hr	70hr

Abbreviations: Conj = conjunctiva; CR = conjunctival redness; hr = hour; LVET = low volume eye test (10  $\mu$ L dose volume)

### **5.2** Roggeband et al. (2000)

Similarly, Roggeband et al. (2000) provides an evaluation of *two products*, a dishwashing liquid (pH 8, contains anionic surfactant, non-ionic surfactant, soap, ethanol, water) and a liquid laundry detergent (pH 7, contains anionic surfactant, non-ionic surfactant, ethanol, water). This study is a direct comparison of modified LVET results to those of a human clinical study. Both rabbits and humans were dosed with either 3  $\mu$ L (dishwashing detergent) or 1  $\mu$ L (liquid laundry detergent) of the test products. There are no corresponding Draize rabbit eye test data. The ocular lesions that were produced in this study and their subsequent time to clear would suggest that these products are mild ocular irritants (**Table 5-2**). The authors conclude that these data support the notion that an accidental exposure would be approximately 10  $\mu$ L or less, and that a volume of 10  $\mu$ L would provide a suitable margin of safety. This is based on: 1) knowledge of the anatomical and physiological characteristics of the eye, and 2) the fact that study participants in Roggeband et al. (2000) could, "only be exposed to 1  $\mu$ L of dishwashing liquid and 3 $\mu$ L of liquid laundry detergent before pre-determined 'cut-off' ocular responses were observed above which it would have been ethically unacceptable to proceed."

530

531

### Table 5-2 Human and Rabbit Eye Responses to a Liquid Laundry Detergent (1 μL, Roggeband et al. 2000)

		Human				Rabbi	it LVET <sup>1</sup>		
Human Volunteer	1 h	our	24	hour	- Animal Number	11	10ur	24 1	nour
, , , , , , , , , , , , , , , , , , , ,	Cornea	Conj	Cornea	Conj		Cornea	Conj	Cornea	Conj
5	0	1/1	0	0/0	28 (c)	0/0	1/1/0	1/2	2/1/1
6	0	1/0	0	0/0	29 (c)	0/0	1/1/0	1/2	2/1/1
21	0	1/0	0	0/0	30 (c)	0/0	1/1/0	0/0	2/1/1
23	1/2	1/0	0	1/0	31 (scs)	0/0	1/1/0	1/4	2/1/0
25	1/1	1/0	0	0/0	32 (scs)	0/0	1/1/0	1/3	2/1/1
27	0	1/0	0	1/0	33 (scs)	0/0	1/1/0	1/4	2/1/1
28	0	1/0	0	0/0					
30	0	0/0	0	0/0					
32	0	1/0	0	0/0					
34	0	1/0	0	0/0					

<sup>(</sup>c) = test substance dosed on the central cornea; Conj = conjunctiva; LVET = low volume eye test; (scs) = test substance dosed on the superior conjunctival sac  $^{1}$ Low volume eye test was modified to use 1  $\mu$ L instead of 10  $\mu$ L

### 5.3 Freeberg et al. (1984)

A series of studies by Freeberg et al. (1984) provides comparisons of data from LVET, Draize rabbit eye test, and human studies or experience. Freeberg et al. presents LVET and Draize rabbit eye test data for 29 cleaning products (laundry products, household cleaning products, and dishwashing products) as compared to human experience data. The ocular lesions that were produced in this study and their subsequent time to clear would suggest that these products are either mild ocular irritants or nonirritants (**Table 5-3**). The human data were obtained from medical records of factory and consumer accidental eye exposures (515 reports over a two-year period). The results indicate that both rabbit LVET and Draize eye tests overpredicted (based on time-to-clear of ocular lesions) the human response based on accidental eye exposure to the cleaning products. The time-to-clear was longer in the Draize eye test than the LVET for the same product, forming the basis for the conclusion that the LVET more closely predicts the human response.

Table 5-3 Summary of Rabbit and Human Accidental Exposure Data from Freeberg et al. (1984)

Species	Test Method	Number of Products	Average ± SD Mean Time to Clear (Days) (Range)	Average ± SD Median Time to Clear (Days) (Range)	Average ± SD Number of Incidents (Range)	
Rabbit	LVET	17	$7.3 \pm 7.2$	$6.2 \pm 8.8$	Not	
			(1.3-28.8)	(0.7-35)	Applicable	
Rabbit	Droigo	Draize	26	$20.4 \pm 7.2$	$20.2 \pm 12.3$	Not
Kabbit	Diaize	20	(3.1-33.5)	(1.4-35)	Applicable	
Human	Experience	29	$2.4 \pm 2.1$	$1.5 \pm 1.5$	$16.2 \pm 8.4$	
Hulliali	data <sup>1</sup>	29	(0.2-9.5)	(0.1-1.8)	(3-68)	

Abbreviations: LVET = low volume eye test; SD = standard deviation

<sup>1</sup>Experience data = combined manufacturing and consumer accidental exposures

### **5.4** Freeberg et al. (1986a)

Freeberg et al. (1986a) compares rabbit eye test results (both LVET and Draize) with those of human studies (both 10  $\mu$ L and 100  $\mu$ L dose volumes) for four cleaning products (a liquid fabric softener, liquid shampoo, liquid hand soap, and liquid laundry detergent). The results indicate that the LVET in rabbits overpredicted human response to 10  $\mu$ L or 100  $\mu$ L of the same product. The ocular lesions (both type and longevity) in the rabbit Draize (100

 $\mu L$ ) were more severe than in the human test using the same volume as the rabbit Draize (100  $\mu L$ ). While the majority of effects in humans were conjunctival, the corneal effects in humans were minimal and transient. The corneal effects in rabbits were more severe and recovered less quickly. The ocular lesions that were produced in this study and their subsequent time to clear would suggest that these products are would be classified as mild ocular irritants based on the Draize eye test results, the LVET, or human results (**Table 5-4**).

Table 5-4 Human Clinical Study and Rabbit Data from Freeberg et al. (1986a)

		Time-to-Clear (hr)						
<b>Test Product</b>	Concentration	Dosing Procedure						
	(% in water)	Rabbit	Hui	man	Rabbit			
		10 μL	10 μL	100 μL	100 µL			
*	60	45	18.9	24.9	45			
Liquid fabric Softener	80	66	12.6	33.6	93			
	100	27	13.2	12.5	84			
Liquid Shampoo	4	5	1.5	2.5	NT			
	16	19.8	1.9	2.6	36.5			
<b>F</b>	20	33	7.5	7.9	63			
	8	24	1.5	31.5	63			
Liquid hand soap	10	42	10.5	9.1	66			
Боир	12	42	1.7	NT	NT			
	2	8.8	2	24.1	27.8			
Liquid laundry detergent	3	19.8	4.7	1.8	60			
<i>8</i>	4	39.8	4.8	19.8	75			

Abbreviations: NT = Not tested

### 5.5 Freeberg et al. (1986b)

Freeberg et al. (1986b) presents LVET and Draize rabbit eye test data for 14 cleaning products (liquid and solid laundry products, liquid and solid household cleaning products, liquid and solid dishwashing products, and liquid shampoos) compared to human experience data. The ocular lesions that were produced in this study and their subsequent

time to clear would suggest that these products would be classified as moderate to severe ocular irritants based on the Draize eye test results, while most would be classified as mild ocular irritants by the LVET (**Table 5-5**). The human data were obtained from medical records of factory and consumer accidental eye exposures (218 reports over an 18-month period). Similar to Freeberg et al. (1986a), rabbit LVET and Draize tests both overpredicted the human response due to accidental eye exposure (based on time-to-clear). Because the time-to-clear was longer for substances tested in the Draize rabbit eye test than in the LVET, the authors concluded that the LVET outcome more closely relates to the human experience than the Draize rabbit eye test.

Table 5-5 Human Accidental Exposure and Rabbit Data from Freeberg et al. (1986b)

Product	Mean Time-to-clear (Days)					
Troduct	Human	Rabbit LVET	Rabbit Draize			
Liquid Laundry Product #1	1.92	26.6	35.0			
Liquid Dishwashing Product #1	0.77	8.2	25.7			
Solid Dishwashing Product #1	0.59	4.6	18.3			
Liquid Dishwashing Product #2	0.43	7.7	11.7			
Liquid Household Cleaning Product #1	0.38	-	11.1			
Liquid Dishwashing Product #3	0.30	3.9	22.2			
Liquid Household Cleaning Product #2	0.23	4.0	15.2			
Solid Household Cleaning Product #1	0.19	1.3	29.2			
Solid Dishwashing Product #1	0.08	2.1	13.8			
Solid Dishwashing Product #1	0.06	2.9	15.1			

582 LVET = low volume eye test

### 6.0 Summary

583

584 Because studies conducted with the LVET have been limited to tests of surfactant-585 containing personal and household cleaning products, the applicability domain for which 586 the LVET can be considered is necessarily restricted to only these product types. Although 587 LVET data have been used by at least one personal care products company to support 588 submission of data to the EPA for registration of an antimicrobial cleaning product, these 589 results were reportedly used by EPA reviewers in a weight-of-evidence approach, with 590 supporting Draize rabbit eye test data and human post-marketing surveillance data (i.e., 591 commercial products for which there is an opportunity for adverse events to be reported by 592 the consumer). 593 As indicated in the studies summarized above, human data on potential ocular hazards are 594 available either from accidental exposures or from clinical studies. Accidental exposures are 595 not generally considered to be a reliable source of the true ocular hazard potential since such 596 exposures are likely immediately followed by flushing the eyes with large volumes of 597 water. Such accidents make definitive quantitative measures of amount and time of 598 exposure impossible to obtain. Although the Draize eye test is reported to be excessively 599 overpredictive of the human response, ethical considerations, based largely on results from 600 the Draize rabbit eye test, are used to limit the types of substances that can be tested in 601 human clinical studies. As a result, comparisons to human clinical study data are based on 602 tests with mild irritant or nonirritant substances. Such data provide little assurance to the 603 regulatory agencies charged with protecting public health that the LVET can provide 604 adequate protection from more severe ocular injuries. 605 Thus, while the LVET is proposed as more likely to approximate the volume of a substance 606 that could enter the human eye experimentally, there are limited data to indicate whether it 607 can accurately identify the ocular hazard of substances known to cause moderate, severe, or 608 permanent human ocular injuries. In contrast, there are no documented instances where a 609 substance with a hazard category determined in the Draize eye test produced a more severe 610 hazard category response in humans following accidental exposures or ethical human 611 studies

### **7.0 References**

- 613 Clean Air Act Amendments of 1990. Public Law 101-549. Available:
- 614 http://www.ehso.com/caa.htm
- 615 CPSC. 1995. Test for eye irritants. 16CFR1500.42.
- Draize J, Woodard G, Calvery H. 1944. Methods for the study of irritation and toxicity of
- substances applied topically to the skin and mucous membranes. J Pharm Exp Ther
- 618 82:377-390.
- 619 EPA. 1998. Health Effects Test Guideline, OPPTS 870.2400 Acute Eye Irritation. EPA
- 712-C-98-195. Washington: U.S. Environmental Protection Agency.
- 621 EPA. 2003. Label Review Manual: 3rd Ed. EPA735-B-03-001. Office of Prevention,
- Pesticides and Toxic Substances. Washington: U.S. Environmental Protection Agency.
- 623 EU. 2001. Commission Directive 2001/59/EC of 6 August 2001 adapting to technical
- progress for the 28th time Council Directive 67/548/EEC on the approximation of the laws,
- regulations and administrative provisions relating to the classification, packaging and
- labelling of dangerous substances. Official Journal of the European Communities L255:1-
- 627 333.
- 628 FDA. 1938. Food, Drug and Cosmetic Act of 1938. Public Law 75-717.
- 629 Federal Environmental Pesticide Control Act. 1972. Public Law 92-516.
- Federal Insecticide, Fungicide and Rodenticide Act. 1947. Public Law 80-102.
- FHSA. 1964. Federal Hazardous Substances Act. Public Law 86-613.
- Freeberg FE, Griffith JF, Bruce RD, Bay PHS. 1984. Correlation of animal test methods
- with human experience for household products. J Toxic Cut. & Ocular Toxic. 1:53-64.
- Freeberg FE, Nixon GA, Reer PJ, Weaver JE, Bruce RD, Griffith JF, et al. 1986a. Human
- and rabbit eye responses to chemical insult. Fundam Appl Toxicol 7: 626-634.
- Freeberg FE, Hooker DT, Griffith JF, 1986b. Correlation of animal test methods with
- human experience for household products: an update. J. Toxic. Cut. & Ocular Toxic. 5:115-
- 638 123.
- 639 Gettings S, Lordo R, Hintze K, Bagley D, Casterton P, Chudkowski M, et al. 1996. The
- 640 CTFA evaluation of alternatives program: an evaluation of in vitro alternatives to the
- Draize primary eye irritation test. (Phase III) surfactant-based formulations. Food Chem
- 642 Toxic 34:79-117.
- Ghassemi A, Sauers LH, Bruner LH, Reer PJ, Hall RH. 1993. Demonstrating the human
- safety of a new household cleaning (HSC) product using alternatives to the Draize eye
- irritation test. Presentation made at the U.S. Society of Toxicology meeting.
- 646 Grant W. 1974. Toxicology of the Eye, 2nd ed. Charles C. Thomas, Springfield, IL.
- 647 Griffith J. Nixon G. Bruce R. Reer P. Bannan E. 1980. Dose-response studies with chemical
- irritants in the albino rabbit eye as a basis for selecting optimum testing conditions for
- predicting hazard to the human eye. Toxic Appl Pharmacol 55:501-513.

- McLaughlin R. 1946. Chemical burns of the human cornea. Am J Ophthamol 29:1355-
- 651 1362.
- OECD. 2002. Test guideline 405, Acute eye irritation/corrosion, adopted February 24,
- 653 1987. In OECD Guidelines for Testing of Chemicals. OECD, Paris.
- Occupational Safety and Health Act of 1970 (OSHA). 1970. Public Law 91-596
- Roggeband R, York M, Pericoi M, Braun W. 2000. Eye irritation responses in rabbit and
- man after single applications of equal volumes of undiluted model liquid detergent products.
- 657 Food Chem Toxic 38:727-734.
- Toxic Substances Control Act of 1976. 1976. Public Law 94-469.
- 659 UN. 2002. OECD Guideline for the Testing of Chemicals. Acute Eye Irritation/Corrosion.
- Adopted: 24<sup>th</sup> April 2002. New York, Geneva: United Nations Publications.
- UN. 2003. Globally Harmonised System of Classification and Labelling of Chemicals
- 662 (GHS). New York, Geneva: United Nations Publications.
- Wilhelmus K. 2001. The Draize eye test. Survey of Ophthalmology. 45: 493-515.